PACT Pharma Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 134

Employees

  • Latest Deal Type
  • Out of Business

PACT Pharma General Information

Description

Developer of personalized adoptive T-cell therapies designed to re-program the immune system to target and eradicate cancer. The company's therapies help in the identification of neo-epitopes that serve as private mutations for cancer and create an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

Contact Information

Website
www.pactpharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Corporate Drive
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 Corporate Drive
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PACT Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 29-Sep-2023 Completed Out of Business
3. Later Stage VC (Series C) 10-Jan-2020 Completed Generating Revenue
2. Early Stage VC (Series B) 25-May-2018 $95M $127M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 20-Dec-2016 $31.7M $31.7M Completed Clinical Trials - Phase 1
To view PACT Pharma’s complete valuation and funding history, request access »

PACT Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A 29,999,999 $0.000100 $0.08 $1 $1 1x $1 20.47%
To view PACT Pharma’s complete cap table history, request access »

PACT Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of personalized adoptive T-cell therapies designed to re-program the immune system to target and eradicate can
Drug Discovery
South San Francisco, CA
134 As of 2022

Boston, MA
 

Newark, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PACT Pharma Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pyxis Oncology Formerly VC-backed Boston, MA
Cellerant Therapeutics Venture Capital-Backed Newark, CA
NexImmune Formerly VC-backed Gaithersburg, MD
ArsenalBio Venture Capital-Backed South San Francisco, CA
TScan Therapeutics Formerly VC-backed Waltham, MA
You’re viewing 5 of 17 competitors. Get the full list »

PACT Pharma Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

PACT Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022294088-A1 Methods for improved t cell receptor sequencing Pending 18-Jun-2021
JP-2024522758-A Improved t cell receptor sequencing method Pending 18-Jun-2021
CA-3222935-A1 Methods for improved t cell receptor sequencing Pending 18-Jun-2021
AU-2022287932-A1 Method of assessing cell products Pending 11-Jun-2021
AU-2022291145-A1 Methods of activating t cells Pending 11-Jun-2021 C12N5/0636
To view PACT Pharma’s complete patent history, request access »

PACT Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PACT Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OGD2 Pharma 07-Oct-2016 Drug Discovery
To view PACT Pharma’s complete investments history, request access »

Ready to get started?

Request a free trial

PACT Pharma FAQs

  • When was PACT Pharma founded?

    PACT Pharma was founded in 2016.

  • Who is the founder of PACT Pharma?

    Juan Jaen Ph.D, Terry Rosen Ph.D, David Baltimore Ph.D, James Heath Ph.D, and Antoni Ribas Ph.D are the founders of PACT Pharma.

  • Where is PACT Pharma headquartered?

    PACT Pharma is headquartered in South San Francisco, CA.

  • What is the size of PACT Pharma?

    PACT Pharma has 134 total employees.

  • What industry is PACT Pharma in?

    PACT Pharma’s primary industry is Drug Discovery.

  • Is PACT Pharma a private or public company?

    PACT Pharma is a Private company.

  • What is PACT Pharma’s current revenue?

    The current revenue for PACT Pharma is .

  • How much funding has PACT Pharma raised over time?

    PACT Pharma has raised $202M.

  • Who are PACT Pharma’s competitors?

    Pyxis Oncology, Cellerant Therapeutics, NexImmune, ArsenalBio, and TScan Therapeutics are some of the 17 competitors of PACT Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »